

**Agilent Technologies, Inc.**  
**Financial Information Index of Schedules**

|                                                                                                                         |      |
|-------------------------------------------------------------------------------------------------------------------------|------|
| Financial Statements:                                                                                                   | Page |
| <a href="#">Condensed Consolidated Statement of Operations (Three Months and Years Ended October 31, 2024 and 2023)</a> | 1    |
| <a href="#">Condensed Consolidated Balance Sheet as of October 31, 2024 and October 31, 2023</a>                        | 2    |
| <a href="#">Condensed Consolidated Statement of Cash Flows (Years Ended October 31, 2024 and 2023)</a>                  | 3    |
| Supplemental Data:                                                                                                      |      |
| <a href="#">Life Sciences and Applied Markets Group (LSAG) Segment Results</a>                                          | 4    |
| <a href="#">Diagnostics and Genomics Group (DGG) Segment Results</a>                                                    | 5    |
| <a href="#">Agilent CrossLab Group (ACG) Segment Results</a>                                                            | 6    |
| Reconciliations:                                                                                                        |      |
| <a href="#">Gross Margin, R&amp;D, SG&amp;A - GAAP to Non-GAAP (Q4'24 vs Q4'23)</a>                                     | 7    |
| <a href="#">Gross Margin, R&amp;D, SG&amp;A - GAAP to Non-GAAP (FY24 vs FY23)</a>                                       | 8    |
| <a href="#">Non-GAAP Income from Operations and Operating Margin (Q4'24 vs Q4'23)</a>                                   | 9    |
| <a href="#">Non-GAAP Income from Operations and Operating Margin (FY24 vs FY23)</a>                                     | 10   |
| <a href="#">Net Income &amp; EPS - Trend</a>                                                                            | 11   |
| <a href="#">Core Revenue by Segment (Q4'24 vs Q4'23)</a>                                                                | 12   |
| <a href="#">Core Revenue by Segment (FY24 vs FY23)</a>                                                                  | 13   |
| <a href="#">Core Revenue by Region (Q4'24 vs Q4'23)</a>                                                                 | 14   |
| <a href="#">Core Revenue by Region (FY24 vs FY23)</a>                                                                   | 15   |
| <a href="#">Core Revenue by Market (Q4'24 vs Q4'23)</a>                                                                 | 16   |
| <a href="#">Core Revenue by Market (FY24 vs FY23)</a>                                                                   | 17   |
| <a href="#">Net Debt to Adjusted EBITDA Ratio</a>                                                                       | 18   |

**AGILENT TECHNOLOGIES, INC.**  
**CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS**  
(In millions, except per share data)  
(Unaudited)  
**PRELIMINARY**

|                                                                 | Three Months Ended<br>October 31, |               | Years Ended<br>October 31, |                 |
|-----------------------------------------------------------------|-----------------------------------|---------------|----------------------------|-----------------|
|                                                                 | 2024                              | 2023          | 2024                       | 2023            |
| Net revenue                                                     | \$ 1,701                          | \$ 1,688      | \$ 6,510                   | \$ 6,833        |
| Costs and expenses:                                             |                                   |               |                            |                 |
| Cost of products and services                                   | 785                               | 773           | 2,975                      | 3,368           |
| Research and development                                        | 111                               | 114           | 479                        | 481             |
| Selling, general and administrative                             | 397                               | 393           | 1,568                      | 1,634           |
| Total costs and expenses                                        | 1,293                             | 1,280         | 5,022                      | 5,483           |
| Income from operations                                          | 408                               | 408           | 1,488                      | 1,350           |
| Interest income                                                 | 24                                | 17            | 80                         | 51              |
| Interest expense                                                | (32)                              | (22)          | (96)                       | (95)            |
| Other income (expense), net                                     | 1                                 | 17            | 49                         | 33              |
| Income before taxes                                             | 401                               | 420           | 1,521                      | 1,339           |
| Provision for (benefit from) income taxes                       | 50                                | (55)          | 232                        | 99              |
| Net income                                                      | <u>\$ 351</u>                     | <u>\$ 475</u> | <u>\$ 1,289</u>            | <u>\$ 1,240</u> |
| Net income per share:                                           |                                   |               |                            |                 |
| Basic                                                           | \$ 1.23                           | \$ 1.63       | \$ 4.44                    | \$ 4.22         |
| Diluted                                                         | \$ 1.22                           | \$ 1.62       | \$ 4.43                    | \$ 4.19         |
| Weighted average shares used in computing net income per share: |                                   |               |                            |                 |
| Basic                                                           | 286                               | 292           | 290                        | 294             |
| Diluted                                                         | 287                               | 293           | 291                        | 296             |

The preliminary income statement is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEET**  
(In millions, except par value and share data)  
(Unaudited)  
**PRELIMINARY**

|                                                                                                                                                                            | October 31,<br>2024 | October 31,<br>2023 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|
| <b>ASSETS</b>                                                                                                                                                              |                     |                     |
| Current assets:                                                                                                                                                            |                     |                     |
| Cash and cash equivalents                                                                                                                                                  | \$ 1,329            | \$ 1,590            |
| Accounts receivable, net                                                                                                                                                   | 1,324               | 1,291               |
| Inventory                                                                                                                                                                  | 972                 | 1,031               |
| Other current assets                                                                                                                                                       | 334                 | 274                 |
| Total current assets                                                                                                                                                       | 3,959               | 4,186               |
| Property, plant and equipment, net                                                                                                                                         | 1,778               | 1,270               |
| Goodwill                                                                                                                                                                   | 4,477               | 3,960               |
| Other intangible assets, net                                                                                                                                               | 547                 | 475                 |
| Long-term investments                                                                                                                                                      | 175                 | 164                 |
| Other assets                                                                                                                                                               | 910                 | 708                 |
| Total assets                                                                                                                                                               | <u>\$ 11,846</u>    | <u>\$ 10,763</u>    |
| <b>LIABILITIES AND EQUITY</b>                                                                                                                                              |                     |                     |
| Current liabilities:                                                                                                                                                       |                     |                     |
| Accounts payable                                                                                                                                                           | \$ 540              | \$ 418              |
| Employee compensation and benefits                                                                                                                                         | 368                 | 371                 |
| Deferred revenue                                                                                                                                                           | 544                 | 505                 |
| Short-term debt                                                                                                                                                            | 45                  | —                   |
| Other accrued liabilities                                                                                                                                                  | 398                 | 309                 |
| Total current liabilities                                                                                                                                                  | 1,895               | 1,603               |
| Long-term debt                                                                                                                                                             | 3,345               | 2,735               |
| Retirement and post-retirement benefits                                                                                                                                    | 130                 | 103                 |
| Other long-term liabilities                                                                                                                                                | 578                 | 477                 |
| Total liabilities                                                                                                                                                          | 5,948               | 4,918               |
| Total Equity:                                                                                                                                                              |                     |                     |
| Stockholders' equity:                                                                                                                                                      |                     |                     |
| Preferred stock; \$0.01 par value; 125,000,000 shares authorized; none issued and outstanding                                                                              | —                   | —                   |
| Common stock; \$0.01 par value, 2,000,000,000 shares authorized; 285,193,011 shares at October 31, 2024 and 292,123,241 shares at October 31, 2023, issued and outstanding | 3                   | 3                   |
| Additional paid-in-capital                                                                                                                                                 | 5,450               | 5,387               |
| Retained earnings                                                                                                                                                          | 750                 | 782                 |
| Accumulated other comprehensive loss                                                                                                                                       | (305)               | (327)               |
| Total stockholders' equity                                                                                                                                                 | 5,898               | 5,845               |
| Total liabilities and stockholders' equity                                                                                                                                 | <u>\$ 11,846</u>    | <u>\$ 10,763</u>    |

The preliminary balance sheet is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS**  
(In millions)  
(Unaudited)  
**PRELIMINARY**

|                                                                                                           | Years Ended         |                     |
|-----------------------------------------------------------------------------------------------------------|---------------------|---------------------|
|                                                                                                           | October 31,<br>2024 | October 31,<br>2023 |
| Cash flows from operating activities:                                                                     |                     |                     |
| Net income                                                                                                | \$ 1,289            | \$ 1,240            |
| Adjustments to reconcile net income to net cash provided by operating activities:                         |                     |                     |
| Depreciation and amortization                                                                             | 257                 | 271                 |
| Share-based compensation                                                                                  | 129                 | 111                 |
| Deferred taxes                                                                                            | (64)                | (56)                |
| Excess and obsolete inventory related charges                                                             | 45                  | 40                  |
| Net (gain) loss on equity securities                                                                      | (6)                 | 41                  |
| Asset impairment charges                                                                                  | 19                  | 277                 |
| Change in fair value of contingent consideration                                                          | —                   | 1                   |
| Net gain on divestiture of business                                                                       | —                   | (43)                |
| Other non-cash (income) expense, net                                                                      | (1)                 | 6                   |
| Changes in assets and liabilities:                                                                        |                     |                     |
| Accounts receivable, net                                                                                  | 7                   | 132                 |
| Inventory                                                                                                 | 34                  | (33)                |
| Accounts payable                                                                                          | 103                 | (171)               |
| Employee compensation and benefits                                                                        | (12)                | (91)                |
| Other assets and liabilities                                                                              | (49)                | 47                  |
| Net cash provided by operating activities <sup>(a)</sup>                                                  | 1,751               | 1,772               |
| Cash flows from investing activities:                                                                     |                     |                     |
| Payments to acquire property, plant and equipment                                                         | (378)               | (298)               |
| Proceeds from sale of equity securities                                                                   | —                   | 5                   |
| Payments to acquire equity securities                                                                     | (5)                 | (8)                 |
| Proceeds from convertible note                                                                            | —                   | 4                   |
| Payments in exchange for convertible note                                                                 | (13)                | (12)                |
| Proceeds from divestiture of business                                                                     | —                   | 50                  |
| Payments to acquire businesses and intangible assets, net of cash acquired                                | (862)               | (51)                |
| Net cash used in investing activities                                                                     | (1,258)             | (310)               |
| Cash flows from financing activities:                                                                     |                     |                     |
| Proceeds from issuance of common stock under employee stock plans                                         | 77                  | 67                  |
| Payment of taxes related to net share settlement of equity awards                                         | (30)                | (54)                |
| Payments for repurchase of common stock                                                                   | (1,150)             | (575)               |
| Payment of excise taxes related to repurchases of common stock                                            | (3)                 | —                   |
| Payments of dividends                                                                                     | (274)               | (265)               |
| Proceeds from issuance of long-term debt                                                                  | 1,197               | —                   |
| Repayments of long-term debt                                                                              | (600)               | —                   |
| Payments of debt issuance costs                                                                           | (9)                 | —                   |
| Net proceeds from (repayment of) short-term debt                                                          | 40                  | (35)                |
| Payment for contingent consideration                                                                      | —                   | (68)                |
| Net cash used in financing activities                                                                     | (752)               | (930)               |
| Effect of exchange rate movements                                                                         | (2)                 | 5                   |
| Net increase (decrease) in cash, cash equivalents and restricted cash                                     | (261)               | 537                 |
| Cash, cash equivalents and restricted cash at beginning of period                                         | 1,593               | 1,056               |
| Cash, cash equivalents and restricted cash at end of period                                               | \$ 1,332            | \$ 1,593            |
| Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet: |                     |                     |
| Cash and cash equivalents                                                                                 | \$ 1,329            | \$ 1,590            |
| Restricted cash, included in other assets                                                                 | 3                   | 3                   |
| Total cash, cash equivalents and restricted cash                                                          | \$ 1,332            | \$ 1,593            |

<sup>(a)</sup> Cash payments included in operating activities:

|                                                |        |        |
|------------------------------------------------|--------|--------|
| Income tax payments, net of refunds received   | \$ 314 | \$ 199 |
| Interest payments, net of capitalized interest | \$ 80  | \$ 89  |

The preliminary cash flow is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**LIFE SCIENCES AND APPLIED MARKETS SEGMENT**  
**(Unaudited)**  
**PRELIMINARY**

(In millions, except margins data)

|                        | 2024   |        |        |        |          |
|------------------------|--------|--------|--------|--------|----------|
|                        | Q1     | Q2     | Q3     | Q4     | Total    |
| Net revenue            | \$ 846 | \$ 754 | \$ 782 | \$ 833 | \$ 3,215 |
| Gross margin %         | 60.2%  | 59.4%  | 60.2%  | 59.1%  | 59.7%    |
| Income from operations | \$ 236 | \$ 186 | \$ 222 | \$ 233 | \$ 877   |
| Operating margin %     | 27.9%  | 24.7%  | 28.4%  | 28.0%  | 27.3%    |

|                        | 2023   |        |        |        |          |
|------------------------|--------|--------|--------|--------|----------|
|                        | Q1     | Q2     | Q3     | Q4     | Total    |
| Net revenue            | \$ 943 | \$ 874 | \$ 854 | \$ 839 | \$ 3,510 |
| Gross margin %         | 61.5%  | 59.8%  | 60.1%  | 59.5%  | 60.3%    |
| Income from operations | \$ 300 | \$ 244 | \$ 265 | \$ 240 | \$ 1,049 |
| Operating margin %     | 31.8%  | 27.9%  | 31.0%  | 28.6%  | 29.9%    |

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and change in fair value of contingent consideration.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**DIAGNOSTICS AND GENOMICS SEGMENT**  
(Unaudited)  
**PRELIMINARY**

(In millions, except margins data)

|                        | 2024   |        |        |        |          |
|------------------------|--------|--------|--------|--------|----------|
|                        | Q1     | Q2     | Q3     | Q4     | Total    |
| Net revenue            | \$ 407 | \$ 417 | \$ 385 | \$ 442 | \$ 1,651 |
| Gross margin %         | 52.8%  | 53.7%  | 51.8%  | 51.5%  | 52.4%    |
| Income from operations | \$ 70  | \$ 86  | \$ 70  | \$ 94  | \$ 320   |
| Operating margin %     | 17.3%  | 20.5%  | 18.3%  | 21.2%  | 19.4%    |

|                        | 2023   |        |        |        |          |
|------------------------|--------|--------|--------|--------|----------|
|                        | Q1     | Q2     | Q3     | Q4     | Total    |
| Net revenue            | \$ 432 | \$ 456 | \$ 422 | \$ 445 | \$ 1,755 |
| Gross margin %         | 52.6%  | 53.7%  | 53.5%  | 53.7%  | 53.4%    |
| Income from operations | \$ 73  | \$ 93  | \$ 96  | \$ 101 | \$ 363   |
| Operating margin %     | 16.9%  | 20.5%  | 22.7%  | 22.7%  | 20.7%    |

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and change in fair value of contingent consideration.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**AGILENT CROSSLAB SEGMENT**  
(Unaudited)  
**PRELIMINARY**

(In millions, except margins data)

|                        | 2024   |        |        |        |          |
|------------------------|--------|--------|--------|--------|----------|
|                        | Q1     | Q2     | Q3     | Q4     | Total    |
| Net revenue            | \$ 405 | \$ 402 | \$ 411 | \$ 426 | \$ 1,644 |
| Gross margin %         | 50.5%  | 50.2%  | 52.1%  | 50.9%  | 50.9%    |
| Income from operations | \$ 122 | \$ 123 | \$ 140 | \$ 139 | \$ 524   |
| Operating margin %     | 30.2%  | 30.5%  | 34.0%  | 32.6%  | 31.9%    |

|                        | 2023   |        |        |        |          |
|------------------------|--------|--------|--------|--------|----------|
|                        | Q1     | Q2     | Q3     | Q4     | Total    |
| Net revenue            | \$ 381 | \$ 387 | \$ 396 | \$ 404 | \$ 1,568 |
| Gross margin %         | 48.5%  | 47.0%  | 50.9%  | 50.4%  | 49.3%    |
| Income from operations | \$ 103 | \$ 103 | \$ 129 | \$ 128 | \$ 463   |
| Operating margin %     | 27.0%  | 26.6%  | 32.7%  | 31.7%  | 29.5%    |

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and change in fair value of contingent consideration.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary segment information is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATION OF NON-GAAP AND GAAP FINANCIAL RESULTS**  
(In millions, except margin data)  
(Unaudited)  
**PRELIMINARY**

| <b>GROSS MARGIN</b>                           | <b>Q4'24</b>    | <b>Gross<br/>Margin %</b> | <b>Q4'23</b>    | <b>Gross<br/>Margin %</b> |
|-----------------------------------------------|-----------------|---------------------------|-----------------|---------------------------|
| <b>GAAP revenue:</b>                          | <b>\$ 1,701</b> |                           | <b>\$ 1,688</b> |                           |
| <b>Gross margin:</b>                          |                 |                           |                 |                           |
| <b>GAAP cost of products and services</b>     | <b>\$ 785</b>   | <b>53.9%</b>              | <b>\$ 773</b>   | <b>54.2%</b>              |
| Non-GAAP adjustments:                         |                 |                           |                 |                           |
| Restructuring and other related costs         | \$ (1)          |                           | \$ (11)         |                           |
| Intangible amortization                       | (19)            |                           | (17)            |                           |
| Transformational initiatives                  | (1)             |                           | (1)             |                           |
| Other                                         | —               |                           | 2               |                           |
| <b>Non-GAAP cost of products and services</b> | <b>\$ 764</b>   | <b>55.1%</b>              | <b>\$ 746</b>   | <b>55.8%</b>              |

| <b>RESEARCH &amp; DEVELOPMENT EXPENSES</b>        | <b>Q4'24</b>    | <b>R&amp;D as % of<br/>Revenue</b> | <b>Q4'23</b>    | <b>R&amp;D as % of<br/>Revenue</b> |
|---------------------------------------------------|-----------------|------------------------------------|-----------------|------------------------------------|
| <b>GAAP revenue:</b>                              | <b>\$ 1,701</b> |                                    | <b>\$ 1,688</b> |                                    |
| <b>GAAP research and development expenses</b>     | <b>\$ 111</b>   | <b>6.5%</b>                        | <b>\$ 114</b>   | <b>6.8%</b>                        |
| Non-GAAP adjustments:                             |                 |                                    |                 |                                    |
| Restructuring and other related costs             | \$ (1)          |                                    | \$ (6)          |                                    |
| Transformational initiatives                      | —               |                                    | 6               |                                    |
| Acquisition and integration costs                 | (1)             |                                    | —               |                                    |
| Other                                             | —               |                                    | 2               |                                    |
| <b>Non-GAAP research and development expenses</b> | <b>\$ 109</b>   | <b>6.4%</b>                        | <b>\$ 116</b>   | <b>6.9%</b>                        |

| <b>SELLING, GENERAL &amp; ADMINISTRATIVE EXPENSES</b>          | <b>Q4'24</b>    | <b>SG&amp;A as % of<br/>Revenue</b> | <b>Q4'23</b>    | <b>SG&amp;A as % of<br/>Revenue</b> |
|----------------------------------------------------------------|-----------------|-------------------------------------|-----------------|-------------------------------------|
| <b>GAAP revenue:</b>                                           | <b>\$ 1,701</b> |                                     | <b>\$ 1,688</b> |                                     |
| <b>GAAP selling, general and administrative expenses</b>       | <b>\$ 397</b>   | <b>23.3%</b>                        | <b>\$ 393</b>   | <b>23.3%</b>                        |
| Non-GAAP adjustments:                                          |                 |                                     |                 |                                     |
| Restructuring and other related costs                          | \$ (3)          |                                     | \$ (29)         |                                     |
| Intangible amortization                                        | (6)             |                                     | (10)            |                                     |
| Transformational initiatives                                   | (5)             |                                     | 1               |                                     |
| Acquisition and integration costs                              | (6)             |                                     | (4)             |                                     |
| Other                                                          | (15)            |                                     | 6               |                                     |
| <b>Non-GAAP selling, general &amp; administrative expenses</b> | <b>\$ 362</b>   | <b>21.3%</b>                        | <b>\$ 357</b>   | <b>21.1%</b>                        |

We provide non-GAAP gross margin, research & development and selling, general & administrative expense amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives and acquisition and integration costs.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company's performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary reconciliation of gross margin, research & development expenses and selling, general & administrative expenses is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATION OF NON-GAAP AND GAAP FINANCIAL RESULTS**  
(In millions, except margin data)  
(Unaudited)  
**PRELIMINARY**

| <b>GROSS MARGIN</b>                           | <b>FY24</b>     | <b>Gross<br/>Margin %</b> | <b>FY23</b>     | <b>Gross<br/>Margin %</b> |
|-----------------------------------------------|-----------------|---------------------------|-----------------|---------------------------|
| <b>GAAP revenue:</b>                          | <b>\$ 6,510</b> |                           | <b>\$ 6,833</b> |                           |
| <b>Gross margin:</b>                          |                 |                           |                 |                           |
| <b>GAAP cost of products and services</b>     | <b>\$ 2,975</b> | <b>54.3%</b>              | <b>\$ 3,368</b> | <b>50.7%</b>              |
| Non-GAAP adjustments:                         |                 |                           |                 |                           |
| Restructuring and other related costs         | (13)            |                           | (11)            |                           |
| Asset impairments                             | (2)             |                           | (253)           |                           |
| Intangible amortization                       | (74)            |                           | (90)            |                           |
| Transformational initiatives                  | (1)             |                           | (3)             |                           |
| Acquisition and integration costs             | 2               |                           | (2)             |                           |
| Other                                         | (1)             |                           | (1)             |                           |
| <b>Non-GAAP cost of products and services</b> | <b>\$ 2,886</b> | <b>55.7%</b>              | <b>\$ 3,008</b> | <b>56.0%</b>              |

| <b>RESEARCH &amp; DEVELOPMENT EXPENSES</b>        | <b>FY24</b>     | <b>R&amp;D as % of<br/>Revenue</b> | <b>FY23</b>     | <b>R&amp;D as % of<br/>Revenue</b> |
|---------------------------------------------------|-----------------|------------------------------------|-----------------|------------------------------------|
| <b>GAAP revenue:</b>                              | <b>\$ 6,510</b> |                                    | <b>\$ 6,833</b> |                                    |
| <b>GAAP research and development expenses</b>     | <b>\$ 479</b>   | <b>7.4%</b>                        | <b>\$ 481</b>   | <b>7.0%</b>                        |
| Non-GAAP adjustments:                             |                 |                                    |                 |                                    |
| Restructuring and other related costs             | (21)            |                                    | (6)             |                                    |
| Asset impairments                                 | (6)             |                                    | (1)             |                                    |
| Transformational initiatives                      | (2)             |                                    | (1)             |                                    |
| Acquisition and integration costs                 | (1)             |                                    | (1)             |                                    |
| <b>Non-GAAP research and development expenses</b> | <b>\$ 449</b>   | <b>6.9%</b>                        | <b>\$ 472</b>   | <b>6.9%</b>                        |

| <b>SELLING, GENERAL &amp; ADMINISTRATIVE EXPENSES</b>          | <b>FY24</b>     | <b>SG&amp;A as % of<br/>Revenue</b> | <b>FY23</b>     | <b>SG&amp;A as % of<br/>Revenue</b> |
|----------------------------------------------------------------|-----------------|-------------------------------------|-----------------|-------------------------------------|
| <b>GAAP revenue:</b>                                           | <b>\$ 6,510</b> |                                     | <b>\$ 6,833</b> |                                     |
| <b>GAAP selling, general and administrative expenses</b>       | <b>\$ 1,568</b> | <b>24.1%</b>                        | <b>\$ 1,634</b> | <b>23.9%</b>                        |
| Non-GAAP adjustments:                                          |                 |                                     |                 |                                     |
| Restructuring and other related costs                          | (42)            |                                     | (29)            |                                     |
| Asset impairments                                              | —               |                                     | (23)            |                                     |
| Intangible amortization                                        | (28)            |                                     | (49)            |                                     |
| Transformational initiatives                                   | (8)             |                                     | (21)            |                                     |
| Acquisition and integration costs                              | (13)            |                                     | (13)            |                                     |
| Change in fair value of contingent consideration               | —               |                                     | (1)             |                                     |
| Other                                                          | (23)            |                                     | (20)            |                                     |
| <b>Non-GAAP selling, general &amp; administrative expenses</b> | <b>\$ 1,454</b> | <b>22.3%</b>                        | <b>\$ 1,478</b> | <b>21.6%</b>                        |

We provide non-GAAP gross margin, research & development and selling, general & administrative expense amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and change in fair value of contingent consideration.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company's performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary reconciliation of gross margin, research & development expenses and selling, general & administrative expenses is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATION OF NON-GAAP INCOME FROM OPERATIONS AND OPERATING MARGINS**  
(In millions, except margin data)  
(Unaudited)  
**PRELIMINARY**

|                                        | Q4'24         | Operating<br>Margin % | Q4'23         | Operating<br>Margin % | Year Over Year<br>Percent Pts<br>Inc/(Dec) |
|----------------------------------------|---------------|-----------------------|---------------|-----------------------|--------------------------------------------|
| <b>GAAP revenue:</b>                   | \$ 1,701      |                       | \$ 1,688      |                       |                                            |
| <b>Income from operations:</b>         |               |                       |               |                       |                                            |
| <b>GAAP Income from operations</b>     | \$ 408        | 24.0%                 | \$ 408        | 24.1%                 |                                            |
| Non-GAAP adjustments:                  |               |                       |               |                       |                                            |
| Restructuring and other related costs  | 5             |                       | 46            |                       |                                            |
| Intangible amortization                | 25            |                       | 27            |                       |                                            |
| Transformational initiatives           | 6             |                       | (6)           |                       |                                            |
| Acquisition and integration costs      | 7             |                       | 4             |                       |                                            |
| Other                                  | 15            |                       | (10)          |                       |                                            |
| <b>Non-GAAP income from operations</b> | <u>\$ 466</u> | 27.4%                 | <u>\$ 469</u> | 27.8%                 | -0.4%                                      |

We provide non-GAAP income from operations and non-GAAP operating margin amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, amortization of intangibles, transformational initiatives and acquisition and integration costs.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company's performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary reconciliation of income from operations and operating margins is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATION OF NON-GAAP INCOME FROM OPERATIONS AND OPERATING MARGINS**  
(In millions, except margin data)  
(Unaudited)  
**PRELIMINARY**

|                                                  | FY24            | Operating<br>Margin % | FY23            | Operating<br>Margin % | Year Over Year<br>Percent Pts<br>Inc/(Dec) |
|--------------------------------------------------|-----------------|-----------------------|-----------------|-----------------------|--------------------------------------------|
| <b>GAAP revenue:</b>                             | \$ 6,510        |                       | \$ 6,833        |                       |                                            |
| <b>Income from operations:</b>                   |                 |                       |                 |                       |                                            |
| <b>GAAP Income from operations</b>               | \$ 1,488        | 22.9%                 | \$ 1,350        | 19.8%                 |                                            |
| Non-GAAP adjustments:                            |                 |                       |                 |                       |                                            |
| Restructuring and other related costs            | 76              |                       | 46              |                       |                                            |
| Asset impairments                                | 8               |                       | 277             |                       |                                            |
| Intangible amortization                          | 102             |                       | 139             |                       |                                            |
| Transformational initiatives                     | 11              |                       | 25              |                       |                                            |
| Acquisition and integration costs                | 12              |                       | 16              |                       |                                            |
| Change in fair value of contingent consideration | —               |                       | 1               |                       |                                            |
| Other                                            | 24              |                       | 21              |                       |                                            |
| <b>Non-GAAP income from operations</b>           | <u>\$ 1,721</u> | 26.4%                 | <u>\$ 1,875</u> | 27.4%                 | -1.0%                                      |

We provide non-GAAP income from operations and non-GAAP operating margin amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and change in fair value of contingent consideration.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company's performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary reconciliation of income from operations and operating margins is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS**  
(In millions, except per share data)  
(Unaudited)  
**PRELIMINARY**

|                                                  | Q4'23         |                | Q1'24         |                | Q2'24         |                | Q3'24         |                | Q4'24         |                | Year Ended<br>October 31, 2023 |                | Year Ended<br>October 31, 2024 |                |
|--------------------------------------------------|---------------|----------------|---------------|----------------|---------------|----------------|---------------|----------------|---------------|----------------|--------------------------------|----------------|--------------------------------|----------------|
|                                                  | Net income    | Diluted<br>EPS | Net income    | Diluted<br>EPS | Net income    | Diluted<br>EPS | Net income    | Diluted<br>EPS | Net income    | Diluted<br>EPS | Net income                     | Diluted<br>EPS | Net income                     | Diluted<br>EPS |
| GAAP net income                                  | \$ 475        | \$ 1.62        | \$ 348        | \$ 1.18        | \$ 308        | \$ 1.05        | \$ 282        | \$ 0.97        | \$ 351        | \$ 1.22        | \$ 1,240                       | \$ 4.19        | \$ 1,289                       | \$ 4.43        |
| Non-GAAP adjustments:                            |               |                |               |                |               |                |               |                |               |                |                                |                |                                |                |
| Restructuring and other related costs            | 46            | 0.16           | 3             | 0.01           | 1             | —              | 67            | 0.23           | 5             | 0.02           | 46                             | 0.16           | 76                             | 0.26           |
| Asset impairments                                | —             | —              | 8             | 0.03           | —             | —              | —             | —              | 11            | 0.04           | 277                            | 0.94           | 19                             | 0.06           |
| Intangible amortization                          | 27            | 0.09           | 26            | 0.09           | 26            | 0.09           | 25            | 0.09           | 25            | 0.09           | 139                            | 0.47           | 102                            | 0.35           |
| Transformational initiatives                     | (6)           | (0.02)         | 3             | 0.01           | 1             | —              | 1             | —              | 6             | 0.02           | 25                             | 0.08           | 11                             | 0.04           |
| Acquisition and integration costs                | 4             | 0.01           | 2             | 0.01           | (1)           | —              | 4             | 0.01           | 7             | 0.02           | 16                             | 0.05           | 12                             | 0.04           |
| Business exit and divestiture costs (gain)       | (43)          | (0.15)         | —             | —              | —             | —              | —             | —              | —             | —              | (43)                           | (0.15)         | —                              | —              |
| Pension settlement loss                          | 4             | 0.01           | —             | —              | —             | —              | —             | —              | 2             | 0.01           | 4                              | 0.01           | 2                              | 0.01           |
| Net (gain) loss on equity securities             | 27            | 0.09           | —             | —              | (1)           | —              | (1)           | —              | 1             | —              | 42                             | 0.14           | (1)                            | —              |
| Change in fair value of contingent consideration | —             | —              | —             | —              | —             | —              | —             | —              | —             | —              | 1                              | —              | —                              | —              |
| Other                                            | (11)          | (0.03)         | (6)           | (0.02)         | 7             | 0.02           | 3             | 0.01           | 13            | 0.05           | 20                             | 0.07           | 17                             | 0.06           |
| Adjustment for taxes <sup>(a)</sup>              | (119)         | (0.40)         | (4)           | (0.02)         | 15            | 0.06           | 4             | 0.01           | (3)           | (0.01)         | (158)                          | (0.52)         | 12                             | 0.04           |
| Non-GAAP net income                              | <u>\$ 404</u> | <u>\$ 1.38</u> | <u>\$ 380</u> | <u>\$ 1.29</u> | <u>\$ 356</u> | <u>\$ 1.22</u> | <u>\$ 385</u> | <u>\$ 1.32</u> | <u>\$ 418</u> | <u>\$ 1.46</u> | <u>\$ 1,609</u>                | <u>\$ 5.44</u> | <u>\$ 1,539</u>                | <u>\$ 5.29</u> |

<sup>(a)</sup> The adjustment for taxes excludes tax expense (benefits) that management believes are not directly related to on-going operations and which are either isolated, temporary or cannot be expected to occur again with any regularity or predictability such as the realized gain/loss due to sale of a business, windfall benefits on stock compensation, and the impact of R&D capitalization under section 174 of the Tax Cuts and Jobs Act of 2017. For the three months ended October 31, 2023, management used a non-GAAP effective tax rate of 13.75%. For the three months ended January 31, 2024, management used a non-GAAP effective tax rate of 13.50%. For the three months ended April 30, 2024, management used a non-GAAP effective tax rate of 12.46%. For the three months ended July 31, 2024, management used a non-GAAP effective tax rate of 13.00%. For the three months ended October 31, 2024, management used a non-GAAP effective tax rate of 11.25%. For the fiscal year ended October 31, 2023, management used a non-GAAP effective tax rate of 13.75%. For the fiscal year ended October 31, 2024, management used a non-GAAP effective tax rate of 12.50%.

We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, business exit and divestiture costs (gain), pension settlement loss, net (gain) loss on equity securities and change in fair value of contingent consideration.

**Restructuring and other related costs** include incremental expenses incurred in the period associated with restructuring programs, usually aimed at changes in business and/or cost structure. Such costs may include one-time termination benefits, facility-related costs and contract termination fees.

**Asset impairments** include assets that have been written down to their fair value.

**Transformational initiatives** include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing, site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system and human resources and financial systems.

**Acquisition and integration costs** include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, tax, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs.

**Business exit and divestiture costs (gain)** include costs and gain associated with business divestitures.

**Pension settlement loss** relates to the relief of the US Retirement Plan pension obligation due to increased lump sum payouts over a specified accounting threshold.

**Net (gain) loss on equity securities** relates to the realized and unrealized mark-to-market adjustments for our marketable and non-marketable equity securities.

**Change in fair value of contingent consideration** represents changes in the fair value estimate of acquisition-related contingent consideration.

**Other** includes certain legal costs and settlements, special compliance costs, acceleration of stock-based compensation expense and other miscellaneous adjustments.

Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results "through the eyes" of management in addition to seeing our GAAP results. This information facilitates our management's internal comparisons to our historical operating results as well as to the operating results of our competitors.

Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company's profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company's performance.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.

The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)  
**PRELIMINARY**

|                                         | Year-over-Year  |                 |  |                |  |  |  |  |  |
|-----------------------------------------|-----------------|-----------------|--|----------------|--|--|--|--|--|
| <u>GAAP Revenue by Segment</u>          | GAAP            |                 |  | Year-over-Year |  |  |  |  |  |
|                                         | Q4'24           | Q4'23           |  | % Change       |  |  |  |  |  |
| Life Sciences and Applied Markets Group | \$ 833          | \$ 839          |  | (1%)           |  |  |  |  |  |
| Diagnostics and Genomics Group          | 442             | 445             |  | (1%)           |  |  |  |  |  |
| Agilent CrossLab Group                  | 426             | 404             |  | 5%             |  |  |  |  |  |
| Agilent                                 | <u>\$ 1,701</u> | <u>\$ 1,688</u> |  | 1%             |  |  |  |  |  |

  

| <u>Non GAAP Revenue by Segment</u>      | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |  | Year-over-Year |  |      | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |                                             | Current Quarter<br>Currency Impact<br><sup>(b)</sup> |
|-----------------------------------------|-----------------------------------------------------|-----------------|--|----------------|--|------|-------------------------------------------------------|---------------------------------------------|------------------------------------------------------|
|                                         | Q4'24                                               | Q4'23           |  | % Change       |  |      | % Change                                              | Percentage Point<br>Impact from<br>Currency |                                                      |
| Life Sciences and Applied Markets Group | \$ 833                                              | \$ 839          |  | (1%)           |  | (1%) | —                                                     | —                                           | \$ 5                                                 |
| Diagnostics and Genomics Group          | 432                                                 | 445             |  | (3%)           |  | (3%) | —                                                     | —                                           | 3                                                    |
| Agilent CrossLab Group                  | 426                                                 | 404             |  | 5%             |  | 5%   | —                                                     | —                                           | 1                                                    |
| Agilent (Core)                          | <u>\$ 1,691</u>                                     | <u>\$ 1,688</u> |  | —              |  | —    | —                                                     | —                                           | <u>\$ 9</u>                                          |

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY SEGMENT**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)  
**PRELIMINARY**

|                                         | Year-over-Year  |                 |                            |  |  |
|-----------------------------------------|-----------------|-----------------|----------------------------|--|--|
| <b>GAAP Revenue by Segment</b>          | GAAP            |                 |                            |  |  |
|                                         | FY24            | FY23            | Year-over-Year<br>% Change |  |  |
| Life Sciences and Applied Markets Group | \$ 3,215        | \$ 3,510        | (8%)                       |  |  |
| Diagnostics and Genomics Group          | 1,651           | 1,755           | (6%)                       |  |  |
| Agilent CrossLab Group                  | 1,644           | 1,568           | 5%                         |  |  |
| Agilent                                 | <u>\$ 6,510</u> | <u>\$ 6,833</u> | <u>(5%)</u>                |  |  |

  

| <b>Non GAAP Revenue by Segment</b>      | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |                            | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |                                             | Current Quarter<br>Currency Impact<br><sup>(b)</sup> |
|-----------------------------------------|-----------------------------------------------------|-----------------|----------------------------|-------------------------------------------------------|---------------------------------------------|------------------------------------------------------|
|                                         | FY24                                                | FY23            | Year-over-Year<br>% Change | Year-over-Year<br>% Change                            | Percentage Point<br>Impact from<br>Currency |                                                      |
| Life Sciences and Applied Markets Group | \$ 3,215                                            | \$ 3,510        | (8%)                       | (8%)                                                  | —                                           | \$ (5)                                               |
| Diagnostics and Genomics Group          | 1,641                                               | 1,748           | (6%)                       | (6%)                                                  | —                                           | 2                                                    |
| Agilent CrossLab Group                  | 1,644                                               | 1,568           | 5%                         | 5%                                                    | —                                           | (4)                                                  |
| Agilent (Core)                          | <u>\$ 6,500</u>                                     | <u>\$ 6,826</u> | <u>(5%)</u>                | <u>(5%)</u>                                           | <u>—</u>                                    | <u>\$ (7)</u>                                        |

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the current year currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY REGION**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)  
**PRELIMINARY**

|                               | Year-over-Year  |                 |                            |
|-------------------------------|-----------------|-----------------|----------------------------|
|                               | GAAP            |                 |                            |
| <u>GAAP Revenue by Region</u> | Q4'24           | Q4'23           | Year-over-Year<br>% Change |
| Americas                      | \$ 680          | \$ 702          | (3%)                       |
| Europe                        | 454             | 433             | 5%                         |
| Asia Pacific                  | 567             | 553             | 3%                         |
| Total Revenue                 | <u>\$ 1,701</u> | <u>\$ 1,688</u> | 1%                         |
| China and Hong Kong           | \$ 312          | \$ 317          | (2%)                       |

  

|                                   | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |                            | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |                                             |                                                   |
|-----------------------------------|-----------------------------------------------------|-----------------|----------------------------|-------------------------------------------------------|---------------------------------------------|---------------------------------------------------|
| <u>Non GAAP Revenue by Region</u> | Q4'24                                               | Q4'23           | Year-over-Year<br>% Change | Year-over-Year<br>% Change                            | Percentage Point<br>Impact from<br>Currency | Current Quarter<br>Currency Impact <sup>(b)</sup> |
| Americas                          | \$ 670                                              | \$ 702          | (5%)                       | (4%)                                                  | -1 ppt                                      | \$ (4)                                            |
| Europe                            | 454                                                 | 433             | 5%                         | 3%                                                    | 2 pts                                       | 9                                                 |
| Asia Pacific                      | 567                                                 | 553             | 3%                         | 2%                                                    | 1 ppt                                       | 4                                                 |
| Total Revenue (Core)              | <u>\$ 1,691</u>                                     | <u>\$ 1,688</u> | —                          | —                                                     | —                                           | <u>\$ 9</u>                                       |
| China and Hong Kong               | \$ 312                                              | \$ 317          | (2%)                       | (3%)                                                  | 1 ppt                                       | \$ 4                                              |

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY REGION**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)  
**PRELIMINARY**

|                               | Year-over-Year  |                 |                         |  |  |  |
|-------------------------------|-----------------|-----------------|-------------------------|--|--|--|
| <u>GAAP Revenue by Region</u> | GAAP            |                 |                         |  |  |  |
|                               | FY24            | FY23            | Year-over-Year % Change |  |  |  |
| Americas                      | \$ 2,573        | \$ 2,732        | (6%)                    |  |  |  |
| Europe                        | 1,770           | 1,754           | 1%                      |  |  |  |
| Asia Pacific                  | 2,167           | 2,347           | (8%)                    |  |  |  |
| Total Revenue                 | <u>\$ 6,510</u> | <u>\$ 6,833</u> | (5%)                    |  |  |  |
| China and Hong Kong           | \$ 1,217        | \$ 1,383        | (12%)                   |  |  |  |

  

| <u>Non GAAP Revenue by Region</u> | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |                         | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |                                       | Current Quarter<br>Currency Impact <sup>(b)</sup> |
|-----------------------------------|-----------------------------------------------------|-----------------|-------------------------|-------------------------------------------------------|---------------------------------------|---------------------------------------------------|
|                                   | FY24                                                | FY23            | Year-over-Year % Change | Year-over-Year % Change                               | Percentage Point Impact from Currency |                                                   |
| Americas                          | \$ 2,563                                            | \$ 2,725        | (6%)                    | (6%)                                                  | —                                     | \$ (2)                                            |
| Europe                            | 1,770                                               | 1,754           | 1%                      | (1%)                                                  | 2 pts                                 | 28                                                |
| Asia Pacific                      | 2,167                                               | 2,347           | (8%)                    | (6%)                                                  | -2 pts                                | (33)                                              |
| Total Revenue (Core)              | <u>\$ 6,500</u>                                     | <u>\$ 6,826</u> | (5%)                    | (5%)                                                  | —                                     | <u>\$ (7)</u>                                     |
| China and Hong Kong               | \$ 1,217                                            | \$ 1,383        | (12%)                   | (11%)                                                 | -1 ppt                                | \$ (8)                                            |

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the current year currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY MARKET**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)  
**PRELIMINARY**

|                                  | Year-over-Year  |                 |                                |
|----------------------------------|-----------------|-----------------|--------------------------------|
|                                  | GAAP            |                 |                                |
| <b>GAAP Revenue by Market</b>    | <b>Q4'24</b>    | <b>Q4'23</b>    | <b>Year-over-Year % Change</b> |
| Pharmaceutical                   | \$ 595          | \$ 590          | 1%                             |
| Academia and government          | 150             | 150             | (1%)                           |
| Diagnostics and clinical         | 255             | 236             | 8%                             |
| Chemicals and advanced materials | 385             | 381             | 1%                             |
| Food                             | 152             | 156             | (2%)                           |
| Environmental and forensics      | 164             | 175             | (6%)                           |
| Total Revenue                    | <u>\$ 1,701</u> | <u>\$ 1,688</u> | 1%                             |

  

|                                  | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |                                | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |                                              |                                                       |
|----------------------------------|-----------------------------------------------------|-----------------|--------------------------------|-------------------------------------------------------|----------------------------------------------|-------------------------------------------------------|
|                                  | <b>Q4'24</b>                                        | <b>Q4'23</b>    | <b>Year-over-Year % Change</b> | <b>Year-over-Year % Change</b>                        | <b>Percentage Point Impact from Currency</b> | <b>Current Quarter Currency Impact <sup>(b)</sup></b> |
| Pharmaceutical                   | \$ 585                                              | \$ 590          | (1%)                           | (1%)                                                  | —                                            | \$ 2                                                  |
| Academia and government          | 150                                                 | 150             | (1%)                           | (1%)                                                  | —                                            | —                                                     |
| Diagnostics and clinical         | 255                                                 | 236             | 8%                             | 7%                                                    | 1 ppt                                        | 2                                                     |
| Chemicals and advanced materials | 385                                                 | 381             | 1%                             | 1%                                                    | —                                            | 3                                                     |
| Food                             | 152                                                 | 156             | (2%)                           | (3%)                                                  | 1 ppt                                        | 1                                                     |
| Environmental and forensics      | 164                                                 | 175             | (6%)                           | (6%)                                                  | —                                            | 1                                                     |
| Total Revenue (Core)             | <u>\$ 1,691</u>                                     | <u>\$ 1,688</u> | —                              | —                                                     | —                                            | <u>\$ 9</u>                                           |

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**RECONCILIATIONS OF REVENUE BY MARKET**  
**EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)**  
(in millions)  
(Unaudited)  
**PRELIMINARY**

|                                  | Year-over-Year  |                 |                                |
|----------------------------------|-----------------|-----------------|--------------------------------|
|                                  | GAAP            |                 |                                |
| <b>GAAP Revenue by Market</b>    | <b>FY24</b>     | <b>FY23</b>     | <b>Year-over-Year % Change</b> |
| Pharmaceutical                   | \$ 2,242        | \$ 2,433        | (8%)                           |
| Academia and government          | 567             | 601             | (6%)                           |
| Diagnostics and clinical         | 964             | 966             | —                              |
| Chemicals and advanced materials | 1,495           | 1,543           | (3%)                           |
| Food                             | 592             | 628             | (6%)                           |
| Environmental and forensics      | 650             | 662             | (2%)                           |
| Total Revenue                    | <u>\$ 6,510</u> | <u>\$ 6,833</u> | (5%)                           |

  

|                                  | Non-GAAP<br>(excluding Acquisitions & Divestitures) |                 |                                | Year-over-Year<br>at Constant Currency <sup>(a)</sup> |                                              |                                                       |
|----------------------------------|-----------------------------------------------------|-----------------|--------------------------------|-------------------------------------------------------|----------------------------------------------|-------------------------------------------------------|
|                                  | <b>FY24</b>                                         | <b>FY23</b>     | <b>Year-over-Year % Change</b> | <b>Year-over-Year % Change</b>                        | <b>Percentage Point Impact from Currency</b> | <b>Current Quarter Currency Impact <sup>(b)</sup></b> |
| Pharmaceutical                   | \$ 2,232                                            | \$ 2,432        | (8%)                           | (8%)                                                  | —                                            | \$ (2)                                                |
| Academia and government          | 567                                                 | 602             | (6%)                           | (6%)                                                  | —                                            | —                                                     |
| Diagnostics and clinical         | 964                                                 | 960             | 1%                             | 1%                                                    | —                                            | —                                                     |
| Chemicals and advanced materials | 1,495                                               | 1,542           | (3%)                           | (3%)                                                  | —                                            | (3)                                                   |
| Food                             | 592                                                 | 628             | (6%)                           | (6%)                                                  | —                                            | (1)                                                   |
| Environmental and forensics      | 650                                                 | 662             | (2%)                           | (2%)                                                  | —                                            | (1)                                                   |
| Total Revenue (Core)             | <u>\$ 6,500</u>                                     | <u>\$ 6,826</u> | (5%)                           | (5%)                                                  | —                                            | <u>\$ (7)</u>                                         |

We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.

<sup>(a)</sup> The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change.

<sup>(b)</sup> The dollar impact from the current year currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change.

The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information.

**AGILENT TECHNOLOGIES, INC.**  
**NET DEBT TO ADJUSTED EBITDA CALCULATION**  
(in millions, except ratio data)  
(Unaudited)  
**PRELIMINARY**

|                         | As of<br>October 31,<br>2024 |
|-------------------------|------------------------------|
| Long-term debt          | \$ 3,345                     |
| Short-term debt         | 45                           |
| Cash & cash equivalents | (1,329)                      |
| <b>Net debt</b>         | <b>\$ 2,061</b>              |

|                                                | Q1'24         | Q2'24         | Q3'24         | Q4'24         | Trailing 12-<br>Month |
|------------------------------------------------|---------------|---------------|---------------|---------------|-----------------------|
| GAAP net income                                | \$ 348        | \$ 308        | \$ 282        | \$ 351        | \$ 1,289              |
| Non-GAAP adjustments:                          |               |               |               |               |                       |
| Asset impairments                              | 8             | —             | —             | 11            | 19                    |
| Restructuring and other related costs          | 3             | 1             | 67            | 5             | 76                    |
| Intangible amortization                        | 26            | 26            | 25            | 25            | 102                   |
| Transformational initiatives                   | 3             | 1             | 1             | 6             | 11                    |
| Acquisition and integration costs              | 2             | (1)           | 4             | 7             | 12                    |
| Pension settlement loss                        | —             | —             | —             | 2             | 2                     |
| Net (gain) loss on equity securities           | —             | (1)           | (1)           | 1             | (1)                   |
| Other                                          | (6)           | 7             | 3             | 13            | 17                    |
| Adjustment for taxes                           | (4)           | 15            | 4             | (3)           | 12                    |
| <b>Non-GAAP net income</b>                     | <b>\$ 380</b> | <b>\$ 356</b> | <b>\$ 385</b> | <b>\$ 418</b> | <b>\$ 1,539</b>       |
| Add:                                           |               |               |               |               |                       |
| (1) Net interest expense                       | \$ 4          | \$ 1          | \$ 3          | \$ 8          | \$ 16                 |
| GAAP provision for (benefit from) income taxes | 55            | 66            | 61            | 50            | 232                   |
| Adjustment for taxes                           | 4             | (15)          | (4)           | 3             | (12)                  |
| (2) Non-GAAP provision for income taxes        | \$ 59         | \$ 51         | \$ 57         | \$ 53         | \$ 220                |
| (3) Depreciation expense                       | \$ 36         | \$ 37         | \$ 38         | \$ 44         | \$ 155                |
| <b>Adjusted EBITDA</b>                         |               |               |               |               | <b>\$ 1,930</b>       |
| <b>Net debt to adjusted EBITDA ratio</b>       |               |               |               |               | <b>1.1</b>            |

The preliminary net debt to adjusted EBITDA ratio is estimated based on our current information.